Efficacy Study of the Octapolar Lead in Patients With Failed Back Surgery Syndrome (FBSS) With Chronic Pain
Recruitment status was Recruiting
Spinal cord stimulation (SCS) has been used for over 40 years to treat neuropathic pain. Various clinical studies have shown a beneficial effect of SCS on pain in patients with Failed Back Surgery Syndrome (FBSS). Since more than 2 years the 8-contact points Octad lead has been used and replaced the 4-contact points Quad lead. Even though it seems that eight electrodes has potential advantage over the four electrodes in case of lead migration or disease progress, no clinical data have been published on the effectiveness of SCS using the octopolar epidural lead. The Octad study intents to assess the effectiveness and technical performance of SCS with the Octad® lead for treatment of chronic pain. This study is not set up as a comparison study between the Octad lead and other SCS leads, such as the Quad lead, because the Octad lead is used in most eligible FBSS patients as the standard of care lead.
The study intends to:
- evaluate the effectiveness of SCS with the Octad® lead on chronic pain in Failed Back Surgery Syndrome patients after 12 months of treatment.
- collect safety data for SCS with the Octad® lead in patients with refractory chronic pain.
Failed Back Surgery Syndrome
Device: Octad® lead (Spinal cord stimulation)
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Octad Study: Evaluation of the Effectiveness of the Octopolar Lead in Patients With Failed Back Surgery Syndrome With Low Back and/or Leg Pain During a One Year Follow-up Period|
- Pain suppression in low back and/or leg [ Time Frame: 12 months ] [ Designated as safety issue: No ]Evaluate the evolution of pain control with the octopolar Octad® lead assessed by a decrease in VAS for leg (and low-back pain separately, if applicable) during 12 months follow-up. Actual pain, the least pain during the last week and the worst pain during the last week are scored.
- adverse events related to SCS [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]Clinical (such as surgery related infections) and technical (such as lead fractures) adverse events will be collected continuously in all patients during a period of 12 months post implant.
- quality of life [ Time Frame: 12 months ] [ Designated as safety issue: No ]Quality of life assessed by EuroQol group - 5 Dimensions (EQ-5D)
- sleep [ Time Frame: 12 months ] [ Designated as safety issue: No ]Sleep is assessed by a 3 item questionnaire on sleep quality, falling asleep and waking up from pain.
- pain medication intake [ Time Frame: 12 months ] [ Designated as safety issue: No ]Data will be collected at specific times on health service resourse use of concomitant pain medication such as opioids.
- Healthcare resource utilization [ Time Frame: 12 months ] [ Designated as safety issue: No ]Data will be collected at specific times on health service resourse use of concomitant non-drug therapy use, such as physiotherapy, related to FBSS.
- preferred stimulation settings [ Time Frame: 12 months ] [ Designated as safety issue: No ]Characterization of pulsegenerator parameters, such as amplitude, pulse width, stimulation frequency, electrode configuration (positive and negative poles), number of stimulation programs, and stimulation duration is done at specific times.
|Study Start Date:||February 2010|
|Estimated Study Completion Date:||August 2012|
|Estimated Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Device: Octad® lead (Spinal cord stimulation)
The use of Spinal Cord Stimulation (SCS) for pain control has already a history of more than 40 years. In SCS, a lead is positioned in the epidural space on the dorsal aspect of the spinal cord so as to produce stimulation induced paraesthesia in the painful area. During the last decades many articles have been published, clearly indicating the effectiveness and safety of SCS with quadripolar leads in the pain management of chronic neuropathic pain, and in particular Failed Back Surgery Syndrome (FBSS). Randomized controlled trials demonstrated that compared with re-operation, SCS provides effective pain relief for at least 3 years and compared with conventional non-surgical neuropathic pain management for at least 2 years.
However, SCS-related complications can occur, that can be divided into surgical complications and hardware complications. The hardware technology has substantially improved over the years. Moreover, electrodes have become smaller in shape and easier to navigate through the epidural space; and finally, internal pulse generators have new programming capabilities and a longer battery life span. All these technological developments led to the application of minimally invasive percutaneous stimulation trials for a variety of patients with chronic neuropathic pain. Turner et al performed a meta-analysis of spinal cord stimulation for failed back surgery syndrome publications and reported hardware complications of 24% lead migration, 7% lead failure and 2% pulse generator failure. While this analysis evaluated studies using older hardware systems, there is first evidence that the rate of these complications is lower currently with new systems. In the recently published PROCESS paper, also using quadripolar electrodes, long term follow-up showed that hardware complications were 14%: lead migration, 3% lead failure and no pulse generator failures.
Generally, patients with radicular pain to the lower extremities respond better to spinal cord stimulation than patients with isolated axial low back pain. However, a few studies have shown that axial low back pain in combination with bilateral leg pain, also respond well to spinal cord stimulation. Both four (e.g. quadripolar Quad lead) and eight (e.g. octapolar Octad® lead) electrodes were shown to be effective in treatment of low back and lower extremity pain, with no apparent advantage of one system over the other. In the recent PROCESS study publication, the reduction of SCS on low-back pain was not-statistically significant when compared to baseline. Even though it seems that eight electrodes may have the potential advantage in case of lead migration or disease progress, no clinical data have been published on the effectiveness of SCS using the octopolar epidural lead. The Octad study is a prospective, multi-center, open-label, non-randomized, interventional study designed to assess the effectiveness and technical performance of SCS with the Octad® lead for treatment of chronic pain. This study is not set up as a comparison study between the Octad lead and other SCS leads, such as the Quad lead, because the Octad lead is used in most eligible FBSS patients as the standard of care lead.
|Contact: Rik Buschman, PhD||31 6 209 101 firstname.lastname@example.org|
|Hospital ZNA Middelheim||Recruiting|
|Antwerpen, Belgium, 2020|
|Contact: S Goossens, MD 32 3 280 39 93|
|Contact: Bryon, MD|
|Principal Investigator: S Goossens, MD|
|Hospital St Jan||Recruiting|
|Brugge, Belgium, 8000|
|Contact: A Ver Donck, MD PhD 32 50 45 25 80 email@example.com|
|Principal Investigator: A Ver Donck, MD PhD|
|Hospital St Blasius||Recruiting|
|Dendermonde, Belgium, 9200|
|Contact: L De Colvenaer, MD PhD firstname.lastname@example.org|
|Principal Investigator: L De Colvenaer, MD PhD|
|Hospital Alma Eeklo||Recruiting|
|Eeklo, Belgium, 9900|
|Contact: J Maeyaert, MD 32 9 224 65 20 email@example.com|
|Principal Investigator: J Maeyaert, MD|
|Hospital Oost Limburg||Recruiting|
|Genk, Belgium, 3600|
|Contact: J Van Zundert, MD PhD 32 89 32 52 54|
|Contact: T Cremers firstname.lastname@example.org|
|Principal Investigator: J Van Zundert, MD PhD|
|Sub-Investigator: P Vanelderen, MD|
|Sub-Investigator: M Puylaert, MD|
|University Hospital Gent||Recruiting|
|Gent, Belgium, 9000|
|Contact: J Devulder, MD PhD 32 9 240 21 11 email@example.com|
|Principal Investigator: J Devulder, MD PhD|
|Sub-Investigator: E Crombez, MD PhD|
|Hospital St Lucas||Recruiting|
|Gent, Belgium, 9000|
|Contact: D Loge, MD 32 9 224 61 11 firstname.lastname@example.org|
|Principal Investigator: D Loge, MD|
|Roeselare, Belgium, 8800|
|Contact: S Brabant, MD 32 51 23 71 11 email@example.com|
|Principal Investigator: S Brabant, MD|
|Roeselare, Belgium, 8800|
|Contact: O De Coster, MD 32 51 23 61 17|
|Contact: E Barbe, MD firstname.lastname@example.org|
|Principal Investigator: O De Coster, MD|
|Hospital Nicolaas||Not yet recruiting|
|Sint-Niklaas, Belgium, 9100|
|Contact: JP Van Buyten, MD 32 3 760 23 18 email@example.com|
|Principal Investigator: JP Van Buyten, MD PhD|
|Zottegem, Belgium, 9620|
|Contact: H Vermeulen, MD firstname.lastname@example.org|
|Principal Investigator: H Vermeulen, MD|
|Stavanger University Hospital||Recruiting|
|Stavanger, Norway, 4068|
|Contact: Roald Baardsen, MD PhD 47 51 51 89 68|
|Principal Investigator: R Baardsen, MD PhD|
|Shalgrenska Hospital||Not yet recruiting|
|Gothenburg, Sweden, 41345|
|Contact: K Gatzinsky, MD PhD 46 31 342 27 44|
|Principal Investigator: K Gatzinsky, MD PhD|
|Principal Investigator:||Ann Ver Donck, MD PhD||Hospital St Jan, Brugge, Belgium|
|Principal Investigator:||Kliment P Gatzinsky, MD PhD||Sahlgrenska University Hospital, Gothenburg, Sweden|
|Principal Investigator:||Roald Baardsen, MD PhD||University hospital Stavanger, Stavanger, Norway|